New Product Planning Excellence Services

STUDY OVERVIEW
BENCHMARK CLASS
STUDY SNAPSHOT
INCLUDED RESEARCH

Pharmaceutical, biotechnology and medical device organizations spend many years developing new products and preparing the marketplace for new healthcare therapies. However, increasing competition, new regulatory requirements, growing safety concerns and relentless cost pressures make the new product planning and development process more complicated and perilous than ever before. New Product Planning leaders can safeguard their products’ success by studying the failures and successes, the benchmarks and best practices of other products that have recently entered the market.

Best Practices, LLC offers its New Product Planning Excellence Services specifically for early-stage marketers who oversee and guide their pipelines from pre-clinical through Phase III development. These vital studies, benchmarks, case studies and best practice analyses will help you bypass pitfalls that have derailed others. New Product Planning leaders and executives can inform their products’ future success using these best practice tools, performance benchmarks, and market insight services.

For more information, please contact Chris Bogan at 919-767-9228.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Consumer Products; Manufacturing; Chemical; Service; Technology

Companies Profiled:
Abbott; Abbott Laboratories; Actelion; Alcon; Allergan; Almirall; Altus Biologics; Amgen; Amylin; ARIAD; Astellas; AstraZeneca; Auxilium; Bausch & Lomb; Baxter International; Bayer; Bayer Healthcare; Biogen Idec; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Pharmaceutical Co.; Dr Reddy's Laboratories; Eli Lilly; EMD Serono; Genentech; Genitope Corporation; Genzyme; GlaxoSmithKline; Human Genome Sciences; Inc.; Inspire Pharmaceuticals; Integrated Communications Corp.; Janssen Cilag Pharmaceutical; Johnson & Johnson; Lilly; Ltd.; Lundbeck; Merck; NeoVista; Nobel Biocare; Novartis; Noven Therapeuticals; Novo Nordisk; Onyx Pharmaceuticals; Ortho Biotech; Pfizer; ProStrakan; Regeneron; Roche; Sanofi-aventis; Shire; Smith & Nephew; Solvay Pharmaceuticals; Spectrum Pharmaceutical; Stiefel; Takeda Pharmaceuticals; Theravance; UCB Pharma; Victory; Xanodyne Pharmaceuticals

Who Can Benefit From These Services?

These services are specifically designed to provide comprehensive coverage on effective strategies and tactics in new product planning. Pharmaceutical executives can use this benchmarking research to learn best practices in New Product Planning management and discover how they can maximize launch activities in competitive markets.

This bundle combines all of the individual research listed below into one easy-to-purchase transaction. Read individual research abstracts by clicking the titles. Return to this page to add the bundle to your cart.

•

New Product Planning Excellence Services

ID: SMS-9

Features:

Pages: 382

Published: Pre-2019

Delivery Format: Online

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6983E47E6961C9AFF852577510033F89A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/983E47E6961C9AFF852577510033F89A?OpenDocument
18
19OpenDocument
203.147.104.120
21
22
23globalbenchmarking.com
24/bestp/domrep.nsf
25SPCL